What is Polybiomics?
Polybiomics is at the forefront of transforming live cell analysis through its proprietary technology. This platform enables the simultaneous and continuous measurement of multiple cellular phenotypes and functions without causing disruption to the cells. Its modular and scalable system integrates multi-parameter monitoring with AI-driven insights, designed to streamline complex workflows across critical sectors including research, pharmaceuticals, biomanufacturing, and clinical applications. By enhancing decision-making and deepening the understanding of live cell behavior, Polybiomics is positioned to capture a significant share of a multi-billion dollar market, offering a comprehensive solution that reduces costs, saves time, and improves experimental reproducibility from early discovery through late-stage development.
How much funding has Polybiomics raised?
Polybiomics has raised a total of $46K across 1 funding round:
Debt
$46K
Debt (2021): $46K with participation from PPP
What's next for Polybiomics?
With substantial expansion capital secured, Polybiomics is poised for a significant scaling phase. The company is expected to leverage this investment to enhance its technological capabilities, broaden its market reach, and potentially expand its operational footprint. Future strategic initiatives will likely focus on further integrating AI-driven insights to provide deeper analytical value to its clients in the biopharmaceutical and research industries. This infusion of capital at a critical growth juncture suggests a clear trajectory towards solidifying its market leadership in advanced live cell analysis solutions.
See full Polybiomics company page
